Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec 19:5:12.
doi: 10.1186/1476-8518-5-12.

An HIV/AIDS Prophylactic vaccine is possible

Qiu Zhong  1 , Ronald B Luftig
Affiliations

An HIV/AIDS Prophylactic vaccine is possible

Qiu Zhong et al. J Immune Based Ther Vaccines. .

Abstract

One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as a mathematician, and a biophysicist.In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs) to incoming and conformationally altered virus after it has bound to CD4+ cells is essential.Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an enhanced number of NAbs.The attempt at increasing CD8+ T cell responses in recent vaccine trials has not worked perhaps because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on increasing NAbs, before high levels of CD8+ T cells are produced.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The cartoon of the L-2 particle has 7–10 times more envelope spikes compared to HIV and shows the double membrane of immature gag. Inside the picture is a TEM image of L-2 particles.
Figure 2
Figure 2
Cryo-EM images: A) The L-2 images show many envelope spikes (red arrows) and a double membrane (blue arrows). B) The control HIV shows few envelope spikes and a single membrane (blue arrow).
See this image and copyright information in PMC

References

    1. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV) Vaccine. 2006;24:4062–4081. doi: 10.1016/j.vaccine.2006.02.031. - DOI - PubMed
    1. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science. 2007;318:28–29. doi: 10.1126/science.318.5847.28. - DOI - PubMed
    1. Fauci AS. The Release of New Date from the HVTN 502 (STEP) HIV Vaccine Study. NIAID NIH. 2007. http://www3.niaid.nih.gov/about/directors/news/step_11707.htm
    1. Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, Ikuta K, Sata T, Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol. 2005;79:5996–6004. doi: 10.1128/JVI.79.10.5996-6004.2005. - DOI - PMC - PubMed
    1. Ohki K, Kishi Y, Nishino Y, Sumiya M, Kimura T, Goto T, Nakai M, Ikuta K. Noninfectious doughnut-shaped human immunodeficiency virus type 1 can induce syncytia mediated by fusion of the particles with CD4-positive cells. J Acquir Immune Defic Syndr. 1991;4:1233–1240. - PubMed